|
1
|
Avossa D, Grandolfo M, Mazzarol F, et al:
Early signs of motoneuron vulnerability in a disease model system:
characterization of transverse slice cultures of spinal cord
isolated from embryonic ALS mice. Neuroscience. 138:1179–1194.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mitchell JD, Callagher P, Gardham J, et
al: Timelines in the diagnostic evaluation of people with suspected
amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) - a
20-year review: can we do better? Amyotroph Lateral Scler.
11:537–541. 2010.PubMed/NCBI
|
|
3
|
Kiernan MC, Vucic S, Cheah BC, et al:
Amyotrophic lateral sclerosis. Lancet. 377:942–955. 2011.
View Article : Google Scholar
|
|
4
|
Zinman L and Cudkowicz M: Emerging targets
and treatments in amyotrophic lateral sclerosis. Lancet Neurology.
10:481–490. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Barber SC and Shaw PJ: Oxidative stress in
ALS: key role in motor neuron injury and therapeutic target. Free
Radical Biol Med. 48:629–641. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Petri S, Körner S and Kiaei M: Nrf2/ARE
signaling pathway: key mediator in oxidative stress and potential
therapeutic target in ALS. Neurol Res Int. 2012:8780302012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Valdmanis PN, Daoud H, Dion PA and Rouleau
GA: Recent advances in the genetics of amyotrophic lateral
sclerosis. Curr Neurol Neurosci Rep. 9:198–205. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Howland DS, Liu J, She Y, et al: Focal
loss of the glutamate transporter EAAT2 in a transgenic rat model
of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc
Natl Acad Sci USA. 99:1604–1609. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gurney ME, Pu H, Chiu AY, et al: Motor
neuron degeneration in mice that express a human Cu,Zn superoxide
dismutase mutation. Science. 264:1772–1775. 1994. View Article : Google Scholar
|
|
10
|
Yu X and Kensler T: Nrf2 as a target for
cancer chemoprevention. Mutat Res. 591:93–102. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Taguchi K, Motohashi H and Yamamoto M:
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response
and cancer evolution. Genes Cells. 16:123–140. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vargas MR and Johnson JA: The Nrf2-ARE
cytoprotective pathway in astrocytes. Expert Rev Mol Med.
11:e172009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hybertson BM, Gao B, Bose SK and McCord
JM: Oxidative stress in health and disease: the therapeutic
potential of Nrf2 activation. Mol Aspects Med. 32:234–246. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mariani E, Polidori MC, Cherubini A and
Mecocci P: Oxidative stress in brain aging, neurodegenerative and
vascular diseases: an overview. J Chromatogr B Analyt Technol
Biomed Life Sci. 827:65–75. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shibata N, Nagai R, Uchida K, et al:
Morphological evidence for lipid peroxidation and protein
glycoxidation in spinal cords from sporadic amyotrophic lateral
sclerosis patients. Brain Res. 917:97–104. 2001. View Article : Google Scholar
|
|
16
|
Sarlette A, Krampfl K, Grothe C, et al:
Nuclear erythroid 2-related factor 2-antioxidative response element
signaling pathway in motor cortex and spinal cord in amyotrophic
lateral sclerosis. J Neuropathol Exp Neurol. 67:1055–1062. 2008.
View Article : Google Scholar
|
|
17
|
Pehar M, Vargas MR, Robinson KM, et al:
Mitochondrial superoxide production and nuclear factor erythroid
2-related factor 2 activation in p75 neurotrophin receptor-induced
motor neuron apoptosis. J Neurosci. 27:7777–7785. 2007. View Article : Google Scholar
|
|
18
|
Neymotin A, Calingasan NY, Wille E, et al:
Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and
CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral
sclerosis. Free Radic Biol Med. 51:88–96. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Malhotra D, Portales-Casamar E, Singh A,
et al: Global mapping of binding sites for Nrf2 identifies novel
targets in cell survival response through ChIP-Seq profiling and
network analysis. Nucleic Acids Res. 38:5718–5734. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Poss KD and Tonegawa S: Reduced stress
defense in heme oxygenase 1-deficient cells. Proc Natl Acad Sci
USA. 94:10925–10930. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Siegel D, Gustafson DL, Dehn DL, et al:
NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger.
Mol Pharmacol. 65:1238–1247. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Slocum SL and Kensler TW: Nrf2: control of
sensitivity to carcinogens. Arch Toxicol. 85:273–284. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vargas MR, Burton NC, Kutzke J, et al:
Absence of Nrf2 or its selective overexpression in neurons and
muscle does not affect survival in ALS-linked mutant hSOD1 mouse
models. PLoS One. 8:e566252013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun MM, Bu H, Li B, et al: Neuroprotective
potential of phase II enzyme inducer diallyl trisulfide. Neurol
Res. 31:23–27. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stack C, Ho D, Wille E, et al:
Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide
improve the behavioral phenotype and brain pathology in a
transgenic mouse model of Huntington’s disease. Free Radic Biol
Med. 49:147–158. 2010.PubMed/NCBI
|
